Global Cancer Drug Development-A Report From the 2022 Accelerating Anticancer Agent Development and Validation...

Area of Science:

• Oncology
• Global Health
• Health Equity

Background:

• Cancer treatment advancements have improved survival, but benefits are unevenly distributed globally.
• Patients in low- and middle-income countries (LMICs) face significant barriers to accessing timely and appropriate cancer care.
• The Accelerating Anticancer Agent Development and Validation workshop highlighted global disparities in cancer drug development and access.

Purpose of the Study:

• To identify key barriers to global cancer drug development and access, particularly in LMICs.
• To explore opportunities for improving access to and affordability of cancer treatments worldwide.
• To emphasize the need for equitable access to high-quality cancer interventions globally.

Main Methods:

• Discussion and identification of barriers during the Accelerating Anticancer Agent Development and Validation workshop in September 2022.
• Focus on challenges in Africa and Latin America.
• Review of potential opportunities and strategies for improvement.

Main Results:

• Key barriers identified include lack of diagnostic services, insufficient human resources, drug accessibility and affordability issues, weak research infrastructure, and regulatory hurdles.
• Opportunities include prioritizing investment in diagnostics, health infrastructure, and workforce planning.
• Streamlined regulatory processes, coordinated drug procurement, and incentivized pricing were discussed as potential solutions.

Conclusions:

• Equitable access to cancer care requires addressing systemic barriers in LMICs.
• Strategic investments in infrastructure, diagnostics, workforce, and regulatory processes are crucial.
• Continued advocacy and development of relevant clinical trials are essential for global cancer equity.